By Annalee Armstrong
U.S. officials have pulled the plug on funding a phase 3 trial for Inovio’s COVID-19 vaccine, telling the biotech that another vaccine is no longer needed as inoculations pick up around the country.
read more
By Fraiser Kansteiner
Alongside bottlenecks around critical materials like plastic bags, COVID-19 vaccine makers are facing another, more complex shortage: people. In fact, gaps in Lonza's staff may have fueled Moderna's recent vaccine shortfalls in countries like Canada, CEO Stéphane Bancel said.
read more
By Dave Muoio
After COVID-19 drove many medical appointments online, one of the nation's largest health systems says a year of virtual care delivery has had major benefits for the environment.
read more
By Andrea Park
Minute Molecular’s tabletop DASH system reads inserted nasal swabs and returns results in about 15 minutes.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Fraiser Kansteiner
Regeneron first unveiled plans to build a $150 million facility at its Tarrytown campus in 2015, but the company is now planning to spend another $330 million for the project, a local news outlet reports.
read more
By Dave Muoio
COVID-19 has triggered a gold rush toward convenient virtual services. Providers and payers must now find a way to marry a tradition of high-quality care with consumer demand for easy access, stakeholders say.
read more
By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky
The U.S. pulled its funding for a phase 3 trial for Inovio's COVID-19 vaccine, telling the company that the country doesn't need another shot. A CDC panel of outside experts is discussing how the U.S. should use Johnson & Johnson's COVID-19 vaccine following repots of rare blood clots. And more headlines.
read more